CancerResearch

November 1, 1994Volume 54 •Number 21PP.5501-5744ISSN0008-5472 •CNREA 8

PLENARY SESSIONAn Integrated View of the Cancer Cell (Donald S. Coffey)

SYMPOSIAThe Cell Cycle and Tumor Suppressor Genes (Thea D.

Tisty)DNA Damage and Repair (Philip C. Hanawalt)Natural Products in Chemoprevention of Cancer (Michael

B. Sporn)Ribozymes and Antisense Oligonucleotides and the

Alteration of Gene Expression (Kevin J. Scanlon)Genetic Susceptibility to Cancer (Kenneth W. Kinzler)Contributions of Environmental Factors to Cancer

(Kenneth Olden)Cell Surface Glycosylation Defining Malignancy (Sen-itiroh

Hakomori)Peripheral Stem Cells and High-Dose Chemotherapy (Peter

J. Quesenberry)Apoptosis (Alan R. Eastman)Biology of Radiation Oncology (H. Rodney Withers and C.

Nonnan Coleman)Biomarkers of Carcinogenesis (David Sidransky)Transcription Factors and Carcinogenesis (Frank J.

Rauscher III)Gene Therapy in Cancer Clinical TrialsTelomeres and Telomerases (Carol W. Greider and Jerry W.

Shay)Extracellular Matrix, Gene Expression, and Cell Signalling

(Hynda K. Kleinman)Mechanistic Basis for Ethnic Differences in Cancer Risk

(Kenneth Olden)Signal Transduction and Gene Control and Development

(James E. Darnell)Angiogenesis (Judah Folkman and Adrian L. Harris)Genes, Development, and Cancer (Eric N. Olson)Growth Factors, Receptors, and Differentiation (Angie

Rizzino)New Strategies and Targets for Chemotherapy (Joseph R.

Bertino and Eddie Reed)Genetic Approaches to Invasion and Metastasis (Robert S.

Kerbel and Patricia S. Steeg)Immunotherapy: Tumor Vaccines (David A. Berd)Graft versus Tumor Effects (Richard J. O'Reilly)Dietary Intervention in Hormonal Carcinogenesis (Diane F.

Bitt and Lovell A. Jones)The Role of Stromal-Epithelial Interactions in Growth and

Neoplasia (Leland W. K. Chung)Cancer Prevention and Intermediate Biomarkers (Peter

Greenwald)

Translational Research in Breast Cancer (Marc E. Lippman)DNA Methylation (Peter A. Jones and Stephen B. Baylin)

METHODS WORKSHOPSGeneral, In Situ, and Quantitative PCR (including

Differential Display) (Saraswati Sukumar)Gene Targeting (Janet Rossant and Andras Nagy)

CONTROVERSY SESSIONSAre Estrogens Implicated in Breast Cancer? (Lovell A.

Jones)Is Mammography Before Age 50 Beneficial?What Are the Limits and Benefits of the PSA Assay? (John

Trachtenberg)Breast Cancer Prevention: What Will We Advise Women

with BRCA1? (Louise C. Strong)What Are the Risks of Electromagnetic Fields In Causing

Cancer? (Mark A. Israel)Is Bone Marrow Transplantation Indicated for Breast

Cancer? (Nancy E. Davidson)

MEET-THE-EXPERT SUNRISE SESSIONSNew Developments in Clinical Pharmacology (Merrill J.

Egorin)Site-specific Gene Expression in Transgenic Animals

(Norman Greenberg)Organ-specific Carcinogenesis (Cheryl Lyn Walker)Modeling and Analyzing Clinical Trials (Steven Piantadosi)Multivariate Determinants of Radiocurability (Richard P.

Hill)Multidrug Resistance (Victor Ling)Cytokines, Vaccines, and Gene Therapy (Jonathan W.

Simons)Tyrosine Kinases and PhosphatasesProstate Cancer (John T. Isaacs)Lung Cancer (Stephen B. Baylin)Colon Cancer (Ronald N. Buick)Pediatric Malignancies (Joseph V. Simone)Hematological Malignancies (Lee M. Nadler)Stem Cell Transplantation (Elizabeth J. Shpall)Molecular Determinants of Multidrug Resistance (Elizabeth

W. Newcomb)Is a Mutagenic Event Involved in Initiation? (Ann R.

Kennedy)Glutathione 5-Transferase (Kenneth D. Tew)Farnesyl Transferase as a Target for Therapy (Alexander

W. Wood)Liver Cancer Etiology and Prevention (John D. Groopman)Biochemical Determinants of Carcinogenesis (Allan B.

Okey)

EDUCATIONAL WORKSHOPSTo Be Announced

Further Information: AACR Office •Public Ledger Building •Suite 816 •150 5. Independence Mall WestPhiladelphia, PA 19106-3483 •TELEPHONE (215) 440-9300 •FAX (215) 440-9313

AMERICAN ASSOCIATION FOR CANCER RESEARCH86th Annual Meeting

Donald S•Coffey, Program ChairpersonMetro Toronto Convention Centre, Toronto, Ontario, Canada

March 18-22, 1995

Titles of Major Sessions(Confirmed Chairpersons in Parentheses)

. CellCultureldentihcationService.UsingIsozymeAnalysis,ImmunofluorescenceandKaryotypicAnalysis(ChromosomeBanding).Contact: Dr.Joseph Kaplan

Children'sHospitalof Michigan3901 Beaubien BoulevardDetroit,Ml 48201(313) 745-5570

CitingContract#N01-CP-33063Cost: Reasonable; inquire with specific

requests.

. GoatAntiseraAgainst:Avian,Bovine,Feline,Murine,and PrimateIntactVirusesand ViralProteins;Antibodiesto lmmunoglobulinsforanumberof species.PreimmuneSeraavailableforsomeVirusAntisera.Contact: Kathleen Whitaker, Ph.D.

BCBRepositoryQualityBiotech,Inc.1667 Davis StreetCamden,NJ 08104(609)966-8000(609) 342-8078 FAXCitingContract#N01-CP-15665

Cost: $7500/5 ml. (Antisera)25.00/5 ml.(PreimmuneSera)65.00/100 ml. (Immunoglobulins)(FrozenMaterial)

. Viruses:Avian,Feline,Murine,andPrimateVirusesProducedinvivoand invitro.Contact: Kathleen Whitaker, Ph.D.

BCBRepositoryQuality Biotech, Inc.1667Davis StreetCamden,NJ 08104(609) 96@8000(609) 342-8078 FAXCitingContract#NO1-CP-15665

Cost: Reasonable, inquire with specificrequests.

. MonoclonalAntibodiesareavailablewithspecificities for synthetic peptides representingtheaminoacid sequencesof the leftend, rightend and activesiteof theoncogeneproductsof avianand mammalianretroviruses.Blockingpeptidesare alsoavailable,as are a limitednumberof cell linesproducingthemonoclonalantibodies.Contact: Kathleen Whitaker, Ph.D.

BCBRepositoryQualityBiotech,Inc.1667 Davis StreetCamden,NJ 08104(609) 96@8000(609) 342-8078 FAXCitingContract#N01-CP-15665

Cost: Peptides —$25.00/mg.AscitesFluid —45.00/mI.CellCulture —100.00/culture.(PlusShippingand Handling)

. Humanserafromdonorswithvariousmalignancies(includingnasopharyngealcarcinoma),non-malignantdisorders,and fromnormalindividuals.Contact: Program Director, Research

Resources,BiologicalCarcinogenesisBranch,

DCE, NCI, NIHExecutivePlazaNorth,Room540Bethesda,MD 20892(301)496-1951(301) 496-2025 FAX

Cost: Shipping and handling charges only.

. TheDivisionofCancerEtiology'sRegistryofExperimentalCancersannouncestheavailabilityof 16 differentstudysetscontaininghistologicslidesof rodenttumors.Thestudysets,withaccompanyingsyllabi,illustratea varietyofspontaneousand inducedtumors,chieflyofrats,mice,and mastomys.Eachset isavailableto cancer investigators worldwide. withoutcharge,forup totwomonths.Requestsorinquiriesshouldbe addressedto:Contact: Registry of Experimental Cancers

NationalCancer InstituteBuilding41, RoomD311NIH, Bethesda,MD 20892USA

U NCI's Chemical Carcinogenesis ResearchInformationSystem(CCRIS)isavailableonlinethroughthe NationalLibraryof Medicine'sToxicologyData Network(TOXNET)system.Throughan interagencyagreementbetweenNCI and NLM, theCCRISdatabasehasbeenbuiltand willbe maintainedand updatedas oneof TOXNET'ssponsoreddatabasesinthebroadareasof chemistry,toxicology,and hazardouswasteinformation.TheCCRISdatabasecontainsevaluateddata and informationoncarcinogens,mutagens,tumorpromotors,cocarcinogens,metabolitesof carcinogens,andcarcinogeninhibitorsderivedfrompublishedreviewarticles,on9oingcurrentawarenesssurveyof primaryliterature,NCI/NTP'sshortand long-termbioassaystudies,the IARCMonographson theEvaluationof CarcinogenicRiskof Chemicals to Man, and special studiesand reports.Contact: Ms. Inge Blackwood

Divisionof Cancer EtiologyNationalCancer InstituteExecutive PlazaNorth, Room 712Bethesda,MD 20892(301)496-1625

•TheNationalCancer Institute,along withtheNationalInstituteof EnvironmentalHealthSciences,theCentersforDiseaseControl,andtheFoodand DrugAdministration,has,formanyyears,supporteda studyby the MichiganDepartmentof PublicHealthdealingwithanaccidentalexposureto polybrominatedbiphenyls.TheMichiganLongTermPBBStudyisa wellmaintainedlongitudinaldatabaseon4,000participants from rural farms in Michigan.Thisgroupwasexposedto polybrominatedbiphenylsthroughconsumptionof contaminatedfarmanimalsand foodproducts.Thecohortwasenrolledand characterizedin 1975-76,establishinga databasecontainingdemographic,healthhistory,medicalcondition,reproductivehistory,bloodand tissueanalyses,and chemical/environmentalexposureinformation.Maprlifeevents—birth,death,cancerand majorillnesseshavebeen confirmedand updatedannually.Theprojecthascurrentlycompletedadetailedrecharaclerizationof all cohort membersand theirchildren.Analysisof the newdata isstillunderway.Thislongitudinaldatabaseisavailableforcollaborativeresearchinvestigatingbiologicaland humanhealthoutcomesfromhalogenatedbiphenylexposure.Cost: Inquire

The Division ofCancer Etiology

National Cancer lnstftuteAnnounces to the Scientific Community the Availability of the FollowingResources/Services for Cancer Related Research As Noted Below:

Contact: Dr. Harold E. B. HumphreyMichiganDepartmentof

PublicHealthDivisionof HealthRiskAssessment3423 North Logan, P.O. Box 30195Lansing,Ml 48909(517) 335-8350

Cost: Free to qualified investigators.

I TheTumorVirusEpidemiologyRepository(flIER) containsseraand otherbiologicalsamplesfrommorethan 13,000patientsand controlsobtainedin 12countries.TheTVERwasestablishedprimarilyto supportcollaborativeresearchon the roleof Epstein-Barrvirus(EBV)in Burkitt'slymphomaand relateddiseases.Seracharacterizedfor humanherpesvirus6 (HHV)antibodiesarealsoavailable.TheTVERcollectionis availablefornewcollaborativestudiesand someindependentresearch.ThemostextensivecollectionsareserumsamplesfrompatientswithBurkitt'slymphoma.Contact: Dr. PaulH. Levine

ViralEpidemiologyBranchDCE,Nd, NIHExecutivePlazaNorth,Room434Bethesda,MD20892(301)496-8115

Cost: Freeto CollaboratingInvestigators;Others:Dependenton ProcessingTime

a TheNationalCancerInstitutehasavailablethe AnimalMorbidity/MortalitySurveyof Collegesof VeterinaryMedicinein NorthAmerica(alsoknownas theVeterinaryMedicalDataProgram).Thisregistryof veterinarymedicalinformationrepresentspatientdataon animalsseenat collaborating veterinaryteachingfacilities;3 millionhospitalepisodeshavebeenabstractedand computerizedin a standardizedrecordformat.Diseaseinformation is coded usingthe schemeof the StandardNomenclatureof VeterinaryDiseaseandOperations.Thecomputertapeswill be madeavailableuponrequest.Contact: Dr. HowardM. Hayes

EnvironmentalEpidemiologyBranchEPB,DCE,NCI,NIHExecutivePlazaNorth,Room443Bethesda,MD20892(301)496-1691

Cost: Inquire

. Humanfibroblastculturesfromindividualsathigh riskof cancer,selectedmembersof cancerpronefamilies,and somenormalfamilymembersareavailable.Thecollectionishistoricalwithunknownviabilityand contaminationstatus.Catalogofcelllinesunavailableandfollowupon manyindividualsis unavailable.Informationrequestsshouldincludepotentialuseofcultures.Contact: Chief,GeneticEpidemiologyBranch

DCE,Nd, NIHExecutivePlazaNorth,Room439Bethesda,MD20892(301)496-4375

Cost: Freeto collaboratinginvestigators.Others:$70/cellline.

a TheNationalInstituteofAllergyandInfectiousDiseasesand the NationalCancerInstitutehavedevelopeda repositoryofbiologicalspecimensfromhomosexualmen.ThespecimenswerecollectedthroughcooperativeagreementswithfourmajorU.S.universitiesfor studiesof thenaturalhistoryof acquiredimmunedeficiencysyndrome(AIDS).Informationaboutapplyingfor collaborativeuseof thesespecimensisavailablefromtheNIAIDProjectOfficerortheNCICo-ProjectOfficer.Contact: Chief,EpidemiologyBranch,AIDS

Program,NIAIDCDCBldg., Room240NationalInstitutesof HealthRockville,MD20852

orto ChiefExtramuralProgramsBranch,EBP,Divisionof CancerEtiology,NCIExecutivePlazaNorth,Room535Rockville,MD20852

S The Epidemiology and Biostatistics Programofthe NationalCancerInstituteand the IndustrywideStudiesBranchof the NationalInstitutefor OccupationalSafetyand Healthhavecreateda ComputerizedOccupationalReferentPopulationSystem(CORPS)whichcontainsdata fromoccupationalcohortstudiesconductedinthepastbyeitheragency.Thisnewlargepopulationof employedpersonscan be used in placeof the generalpopulationas the referentgroup inoccupationalcohortstudiesto amelioratethe healthyworkereffect.Populationsfromstandardizedmortalitystudiesandproportionalmortalitystudieshavebeenassembled.Potentialusersmayrequestmortalityratesintheformatrequiredbysoftwarecommonlyusedto analyzeepidemiologicoccupationaldata(i.e.,Monson,NIOSHLifeTable,OCMAP,OlE).Ratefilesmaybe requestedby race,gender,blue/whitecollarstatus,minimumemploymentduration,state,and othercharacteristics.Contact: SheliaHoarZahm,Sc.D.

OccupationalStudiesSectionEEB,EBP,DCE,NCI,NIHExecutivePlazaNorth,Room418Bethesda,MD20892Phone: (301)496-9093Fax: (301)402-1819

Cost: Free

U TheEpidemiologyandBiostatisticsProgramoftheNationalCancerInstitute(NCI)hasdeveloped an OccupationalMortalityAnalysissoftwaresystemwhichcalculatesProportionateMortalityRatios,ProportionateCancerMortalityRatios,orMortalityOdds Ratiosusingoccupationalinformationon thedeathcertificatesfrom24 statesfor1984-1989.Thedatawereassembledthrough

a collaborativeeffortinvolvingtheNationalCenterfor HealthStatistics,the NationalInstituteforOccupationalSafetyand Healthand NCI.Theprogram is userfriendlyand allowsanalysisof databy(1)occupation,industry,or occupationallindustrycombinations;(2)age group;(3) statesor geegraphicregions;(4) racegroups,(blackandwhite);(5) sex,and (6) underlyingcausesofdeath.Theprogramis writteninWylburCommandProceduresand is exportableto mostmainframes.Contact: (Toobtainthe programand relate

information):MustafaDosemeci,Ph.D.OccupationalStudiesSectionEBP,EDCE,Nd, NIHExecutivePlazaNorth,Room418Bethesda,MD20892Phone: (301)496-9093Fax: (301)402-1819

(Forquestionsconcerningthenatureandsourceoftheoccupationalmortalitydata):

JeffMaurer,MS.MortalityStatisticsBranchDivisionof VitalStatistics,NCHS6525BelcrestRd.,Room840Hyattsville,MD20782Phone: (301)436-8884Fax: (301)436-7066

Cost: Free

. TheEpidemiologyandBiostatisticsProgramoftheNationalCancerInstitute(NCI)hasdevelopeda computer-aidedoccupationalandindustrialcodesearchingprogram(CODESEARCH)whichallowsthecodeassignertoselectappropriatecodesfromexistingclassificationsystemsfor job or industrialtitlesfromworkhistoriesof thestudysubjects.Theprogramis userfriendlyand allowssearchesfromfouroccupationalClassificationSystems(1977StandardOccupationalClassifkationManual[SOd;1980SOC;1970BureauofCensusOccupationalC@SSdiCat1OnSystem [BOCOC]; and 1980 BOCOC,andfourindustrialclassificationsystems(1972StandardIndustrialClassificationSystem[SIC);1987SIC;1970Bureauof CensusIndustrialClassificationSystem[BOCIC);and 1980BOCIC).Theprogramis writtenusingPC-Clippersoftwareandisexportabletomost486PCs.Contact: MustafaDosemeci,Ph.D.

OccupationalStudiesSectionEBP,DdE,NCI,NIHExecutivePlazaNorth,Room418Bethesda,MD20892Phone: (301)496-9093Fax: (301)402-1819

Cost: Free

U Analytical support for the collection, separation,andelucidationofenvironmentalcarcinogensincludingcombustionandsmoking-relatedexposures.A contractorwithexperienceinthedevelopmentofanalyticalmethodsforthedeterminationof constituentsof cigarettesmokeandcigarettesmokecondensates,andofspecialtyinstrumentationfor inhalationtoxicologyis availableto assistqualifiedinvestigatorswithparticularinterestinhumanandanimalmodelexposureto environmentaland sidestreamsmoke.Extensivechemicalinformationon smokeandsmokecondensatecomponentsisavailable.Contact: HaroldE.Seifried,Ph.D.

Chemicaland PhysicalCarcinogenesisBranch,DdE,NCI

ExecutivePlazaNorth,Room700Bethesda,MD20892(301)496-5471(301)496-1040FAX

Cost: Inquire

. ChemicaldarcinogenReferenceStandardRepository:Referencequantitiesof over750compoundsareavailable.Thenewestadditionsarediluteaqueousstandardsof PAHdeoxyguanosine-3'-monophosphatesfor Randerath @Ppostlabellingassays.Otherclassesof availablecompoundsare:foodmutagens,polynucleararomatichydrocarbons(PAH),PAHmetabolites,radiolabeledPAHmetabolites,nitrogenheterocydes, nitrosamines/nitrosamides,aromaticamines,aromaticaminemetabolites,azo/azoxyaromatics,inorganics,nitroaromatics,pesticides,pharmaceuticals,naturalproducts,dyes,dioxinsand chiorinatedaliphatics.A numberof radiolabeledPAHadducts,metabolitesandnitrosaminesarealsoavailable.DataSheetsprovidedwiththecompoundsincludechemicaland physicalproperties,analyticaldata,hazards,storage,and handlinginformation.datalog availableuponrequest.

Contact: Manager,NCIChemicalCarcinogenRepository

MidwestResearchInstitute425VolkerBoulevardKansasCity,MO64110(816)753-7600,Ext.523(816)753-3664FAX

Manager,Ndl RadiolabeledChemicalRepository

CHEMSYNScienceLaboratories13605W.96thTerraceLexena,KS66215(913)541-0525(913)888-3582FAX

Cost: Subjectto chemicalclasscodeandquantity(seecatalog)includeshandlingand shippingcharges.

SpecialLecturesPierreChambonI Strasbourg,FranceRonaldM.EvansI LaJolla,CA

HeterodimerizationandProtein/ProteinInteractionsHendrikG.StunnenbergI Heidelberg,GermanyBjomVennstromI Stockholm,SwedenMagnusPtahl/ LaJolla,CAChristopherK.Glass/ SanDiego,CA

ReceptorStructurePeterE.WrightI LaJolla,CA

EmbryonicDevelopmentGregorElcheleI Houston,TXLeeAnnNiswanderI NewYork,NYCarlThummelI SaftLakeCity,UTJeremyBrockesI London,England

Actionsof RetinoidsRichardHeymanI LaJolla,CAArthurLevinI Nutley,NJJochenBuckI NewYork,NYMichaelB.SpomI Bethesda,MDLorraineJ.GudasI NewYork,NY

AnalysisofDiseaseBenjaminG.NealI Boston,MAKennethKorachI ResearchTrianglePark,NCHughesdeTheI Paris,FranceGUntherSchUtzI Heidelberg,Germany

OrphanReceptorsDavidJ. MangelsdOrfI Dallas,TXVincentGlguere/ Toronto,Ontario,CanadaKeithParkerI Durham,NCJan@AkeGustafssonI Huddinge,Sweden

SteroidHormonesBertW.O'MalleyI Houston,TXDonaldP.McDonnellI Durham,NCBenitaS.KatzenellenbogenI Urbana,IL

VitaminDJohnWesleyPike/ LaJolla,CALeonardP.FreedmanI NewYork.NY

Applicantsareencouragedtosubmitabstractsforposterpresentation.

InformationandApplicationFormsAmerican Association for Cancer ResearchPublicLedgerBuilding,Suite816150 South Independence Mall WestPhiladelphia,PA 19106-348321 5-440-9300 21 5-440-931 3 (FAX)

MECHANISMOFACTIONOFRETINOIDS,VITAMIND,ANDSTEROIDHORMONES

AnAACRSpecialConferencein CancerResearch

January14-19,1995WhistlerResortandConferenceCentre

Whistler,BritishColumbia,Canada

CONFERENCE CHAIRPERSONSMichaelB.SpornI Bethesda,MDRonaldM.EvansI LaJolla,CA

DavidJ.MangelsdorfI Dallas,TX

PROGRAM COMMI1TEEVincentGiguere/ Toronto,Ontario,Canada

JohnWesleyPike/ LaJolla,CA

SCIENTIFIC PROGRAM

AUDIO CASSETIE DISCOUNTSl-5cassettes $11.506-Il cassettes 5% DISCOUNTl2-24cassettes 10%DISCOUNT25-48cassettes 15% DISCOUNT49+ 20%DISCOUNT

Programsconsistof 1,2,or 3cassettes.Pricesarelistedaftereachprogramtitle.

0 CAN-431Symposium9:TranscriptionalControlofCellProliferationandDifferentiation(2cassettes,$23.00)

0 CAN-432 MinisymposiumEpidemiology I: CancerEpidemiology I: (2 cassettes,$23.00)

0 CAN-433MinisymposiumCarcinogenesis9:GenomicInstability(3cassettes,$34.50)0 CAN-434MinisymposiumClinicalInvestigations6:BreastCancerI(3cassettes,$34.50)

0 CAN-435MinisymposiumMolecularBiologylBiochemistry6:AdvancedCancerCytogenetics(3cassettes,$34.50)

0 CAN-436MinisymposiumExperimentalTherapeutics13:TopoisomeraseII:(3cassettes,$3430)

0 CAN-437ControversySessionI: FatandBreastCancer:CananInterventionTrialResolvetheIssue?(1cassette,$11.S0)

0 CAN-438ThirdAmericanCancerSocietyAwardLectureonCancerEpidemiologyandPrevention:ThePreventionof Hormone-inducedCancers,BrianE.Henderson(I cassette,$11.50)

0 CAN-439MinisymposiumBiologyI1:CellAdhesionandExtracellularMatrixMolecules(3cassettes,$34.50)

0 CAN-440MinisymposiumCarcinogenesis12:TumorSuppressorGenesII: (3cassettes,$34.50)

0 CAN-441MinisymposiumClinicalInvestigations9:SolidlumorsIll: (3cassettes,$34.50)0 CAN-442MinisymposiumMolecularBiology/Biochemistry9:ControlofGeneExpressionI:

(3cassettes,$34.50)

0 CAN-443MinisymposiumExpenmentalTherapeutics21:ModulationoftheMultidrugResistancePhenotype(2cassettes,$23.00)

0 CAN-444Symposium10:ProgrammedCellDeath(2cassettes,$23.00)0 CAN-445SymposiumII: NewStrategiesforlmmunologicallntervention(3cassettes,

$34.50)0 CAN-446Symposium12:DietandCancer:TheRoleofProtectiveFactors(2cassettes,

$23.00)

0 CAN-447Symposium13:BasicandClinicalAspectsofProstateCancer(2cassettes,$23.00)

0 CAN-448ControversySession2:IsMultidrugResistanceanImportantFactorinTherapeuticOutcome?(2 cassettes,$23.00)

0 CAN-449AACRAnnualBusinessMeeting(I cassette,$1I30)

0 CAN-450MeettheExpertSunriseSession:IntrinsicandAcquiredResistancetoAntimetabolites,JosephR.Bertino(I cassette,$1130)

0 CAN-451MeettheExpertSunriseSession:PathologyandEpidemiologyofHelicobactorpylonInfection—IsThereaCancerLink?PelayoCorrea(I cassette,$1ISO)

0 CAN-452MeettheExpertSunriseSession:MolecularAspectsofBreastCancerProgression,HeleneS.Smith( I cassette,$1ISO)

0 CAN-453MinisymposiumClinicalInvestigations12:RoleofOncogenesinSolidTumors(2cassettes,$23.00)

0 CAN-454MinisymposiumBiologyIS:CellularandGeneticFactorsinMetastasis(3cassettes,$34.50)

0 CAN-455MinisymposiumCarcinogenesis16:TumorPromotion11(3cassettes,$34.50)0 CAN-456MinisymposiumMolecularBiology/Biochemistry13:DNALesions:Their

RecognitionandRepair(3cassettes,$3430)

0 CAN-457MinisymposiumExperimentalTherapeutics27:TyrosineKinasesandProteinKinaseC asAntineoplasticDrugTargets(3cassettes,$34.50)

0 CAN-458Symposium14:BasicScienceApproachestoBreastCancer(2cassettes,$23.00)0 CAN-459SymposiumIS:GeneticBasisforlumorCellSensitivitytoRadiation(2cassettes,

$23.00)

a CAN-460Symposium16:IntermediateEndpointsinCancerPrevention(2cassettes,$23.00)0 CAN-461Symposium17:Pharmacogenetics:RoleofDrugMetabolismPolymorphismsin

CancerChemotherapy(2cassettes,$23.00)

0 CAN-462ControversySession3:IsBoneMarrowTransplantationIndicatedforAdultAcuteLeukemiain FirstRemission?(I cassette,$11.50)

0 CAN-463EighteenthRichardandHindaRosenthalFoundationAwardLecture:AngiogenesisasaTargetfor CancerTherapy,MarcE. Lippman(I cassette,$11.50)

0 CAN-464PublicEducationSession:TheFundingCrisisinCancerResearch:WhatCanWeDo?(l cassette,$1130)

0 CAN-465MinisymposiumBiology20:ApoptosisIII(3cassettes,$34.50)

0 CAN-466MinisymposiumImmunology/BiologicalTherapy10:TumorAntigensandTumorVaccines(3cassettes,$34.50)

0 CAN401MeettheExpertSunriseSession:Anti-GrowthFactorTherapytoPreventandTreatLungCancer:A NewHorizonoraFantasy?PaulA.Bunn,Jr.(I cassette,$11.50)

0 CAN-402MeettheExpertSunriseSession:CancerCellStructureandChaos,DonaldS.Coffey ( I cassette, $11.50)

0 CAN-403MeettheExpertSunriseSession:MolecularBiologyofHematopoieticMalignancies,CarloM.Croce(1cassette,$1ISO)

0 CAN-404MeettheExpertSunriseSession:NewFrontiersinChemoprevention:BasicSciencetotheClinic,WaunKiHong(I cassette,$11.50)

0 CAN-405PlenarySession:BiologicalandClinicalRolesofGeneticMarkers(2cassettes,$23.00)

0 CAN-406MinisymposiumEndocrinology1:HormonalCarcinogenesisandProgression(2cassettes,$23.00)

0 CAN-407MinisymposiumImmunology/BiologicalTherapyI:Antibody-basedlherapyofCancer(3cassettes,$34.50)

0 CAN-408MinisymposiumClinicalInvestigations1:ClinicalPharmacology/PhaseIStudies(3cassettes,$34.50)

0 CAN-409MinisymposiumCarcinogenesisI:AngiogenesisandNeoplasia(3cassettes,$34.50)

0 CAN-410MinisymposiumExperimentalTherapeuticsI:TopoisomeraseI(3cassettes,$34.50)

0 CAN-41I Thirty-FourthG.H.A.ClowesMemorialAwardLecture:GeneticAnalysisofHumanBreastCancer,Mary-ClaireKing(I cassette,$11.S0)

0 CAN-412MinisymposiumPrevention2:TranslationofChemopreventiontoHumans(3cassettes,$34.50)

0 CAN-413MinisymposiumBiology4:SignalTransductionandOncogenesinBreastCancer(3cassettes,$34.50)

0 CAN-414MinisymposiumClinicalInvestigations3:DrugResistance(3cassettes,$34.50)0 CAN-415MinisymposiumExperimentalTherapeutics7:P-GlycoproteinII (3cassettes,

$34.50)

0 CAN-417SymposiumI:RecentAdvancesinEnvironmentalCarcinogenesis(2cassettes,$23.00)

0 CAN-418Symposium2:CellularSignaling(2cassettes,$23.00)DCAN-419Symposium3:AIDS-relatedMalignancies(2cassettes,$23.00)0 CAN-420Symposium4:SolidTumorPhysiologyandTherapeuticApproaches(2cassettes,

$23.00)

0 CAN-421Symposium5:ConductingCancerResearchamongMinorityPopulationsintheUnitedStates(2cassettes,$23.00)

0 CAN-422PresidentialAddress:UVRadiationandImmunology:SomethingNewundertheSun,MargaretL.Kripke;PresentationoftheSecondGertrudeElionCancerResearchAward(I cassette,$1130)

0 CAN-423MinorityIssuesCommitteeSymposium:SurvivalandSuccessinCancerResearch:TowardtheYear2000(2cassettes,$23.00)

0 CAN-424MeettheExpenSunriseSession:ModulationofGeneExpressioninMultidrugresistantTumorCells,JuneL. Biedler( I cassette,$1130)

0 CAN-425MeettheExpertSunriseSession:CytochromeP4501A1:AnExerciseinRegulation,EdwardBresnick(I cassette,$1I30)

0 CAN-426MeettheExpertSunriseSession:PhysiologicalResistancetotheTreatmentofSolidTumors,RakeshK.Jam(I cassette,$1ISO)

0 CAN-427MeettheExpertSunriseSession:ChemopreventionofBreastCancer—AlternativestoTamoxifenandRetinoids,LeeW.Wattenberg(1cassette,$11.50)

DCAN-428Symposium6:HematologicalMalignancies:Biologyandl'herapy(2cassettes,$23.00)

aCAN-429Symposium7:NewApproachestoCancerImmunotherapy(2cassettes,$23.00)0 CAN-430Symposium8:RetinoidsandCancer(2cassettes,$23.00)

I ____ 1 AUDIOCASSETFEORDERFORM@ ____iLI@i@@i85thAnnualMeeting•AmericanAssodationforCancerResearch___[IlL •. Li Programs consist ofeither ltape/$l 1 .50, 2 tapes/$23.OO, or 3 tapes/$34.50(PRIcrs INDICATEDAFJ'ER EACH ru@) [j@. •,@ j

VIDEO CASSETFE DISCOUNT

0 SAVE 10%ON ENTIRE SET OF 11 VIDEOS, $386

$15.00 PERTAPESURCHARGE FOR PALCONVERSIONS

NAME_________________________________________________ TITLE________________________________________________

ORGANIZATION

ADDRESS(NO P0 BOXES) . CITY__________________ STATE_____ ZIP ____________

SIGNATURE________________________________________________ TELEPHONE(

I PLEASECOMPLETEANDRETURNENTIREFORM_________SENDTO:TEACH‘EM.160EASTILLINOISST..CHICAGO,IL60611

PHONE: (3 I2) 467-0424@ FAX: (3 I2) 467-927 I@ TOLL-FREE: I-800-225-3775SUB-TOTALAUDIQTAPEORDER S ___________

SUB-TOTALVIOEQTAPEORDER S __________

(ILRESIDENTSADD8.75%SALESTAX) S ___________AU@D.I0$.4.OOSHIPPING&HANDLING5 $400@lQ@Q$4.00S&H($24MAX)5

0 CAN-467MinisymposiumRadiobiology/RadiationOncology5:IrradiationandtheCellCycle(2cassettes,$23.00)

0 CAN-468MinisymposiumMolecularBiologylBiochemistry17:p53Function(3cassettes,$34.50)

0 CAN-469MinisymposiumExperimentalTherapeutics33:GeneTherapyII:(3cassettes,$34.50)

0 CAN-470Symposium18:PotentialApplicationsofAdvancesinCellandMolecularBiologyto New TherapiesforLungCancer(2 cassettes,$23.00)

0 CAN-471Symposium19:GenomicImprintingandItsRoleinCancer(2cassettes,$23.00)

0 CAN-472Symposium20:NovelStrategiesinChemicalPreventionofCancer(2cassettes,$23.00)

0 CAN-473Symposium21:MechanismsandCircumventionofDrugResistance(2cassettes,$23.00)

0 CAN-474ThirteenthCorneliusP.RhoadsMemorialAwardLecture:GeneticSuppressorElements:NewToolsforMolecularOncology,IgorB.Roninson(I cassette,$11.S0)

0 CAN-475MeettheExpertSunriseSession:MolecularBasisandFunctionalRoleofGlycosphingolipidsandGlycoproteinsinTumorProgressionandPrevention,SenitirohHakomori(I cassette,$11.50)

0 CAN-476MeettheExpertSunriseSession:VerapamilandOtherMilestonesfortheTherapyofMultidrugResistance,TakashiTsuruo(I cassette,$11.S0)

0 CAN-477MeettheExpertSunriseSession:TheBiologyofRadiationOncology,H.RodneyWithersandWilliamH. McBride(I cassette,$11.50)

0 CAN-478Symposium22:TumorSuppressorGenesandCellCycleControl(2cassettes,$23.00)

0 CAN-479Symposium23:HormonalCarcinogenesis:EpidemiologicalandMechanisticStudies(2 cassettes,$23.00)

0 CAN-480Symposium24:TopoisomeraseIInhibitors:MoleculestoMedicine(2cassettes,$23.00)

0 CAN-48lMultidisciplinarySessionI:CytokineBiologyandTherapy(2cassettes,$23.00)0 CAN-482MultidisciplinarySession2:TargetingrasforCancerChemotherapy(2cassettes,

$23.00)

0 CAN-483MinisymposiumClinicalInvestigations15:Cytogenetics/MolecularGenetics(3 cassettes,$34.50)

0 CAN-484MinisymposiumClinicalInvestigations16:GeneTherapy(3cassettes,$34.50)0 CAN-485MinisymposiumBiology23:ProteasesandTheirlnhibitorsinDifferentiationand

Cancer(3 cassettes,$34.50)

0 CAN-486ThirteenthBruceF.CainMemorialAwardLecture:CamptothecinandTaxol:FromDiscoveryto Clinical Usage,MansukhC. Waniand MonroeE. Wall(1 cassette,$11.S0)

0 CAN-487MinisymposiumCarcinogenesis25:TumorProgressionII(3cassettes,$3430)0 CAN-488MinisymposiumExperimentalTherapeutics45:Antisense(3cassettes,$34.50)0 CAN-489MinisymposiumClinicalInvestigations19:ClinicalMolecularStudies(3cassettes,

$34.50)

0 CAN-490MinisymposiumMolecularBiologylBiochemistry22:TyrosineKinasesandPhosphatases(3 cassettes,$34.50)

0 CAN-49lMinisymposiumExperimentalTherapeutics46:ThymidylateSynthase(3cassettes,$34.50)

0 CAN-492Symposium25:IntegrationofCytokinesandRadiation:BiologicalBasisandPreliminaryClinicalTrials(2cassettes,$23.00)

0 CAN-493Symposium26:CellAdhesioninInvasionandMetastasis(2cassettes,$23.00)

THE FOLLOWING PROGRAMS ARE AVAILABLE ON

VIDEO CASSEtTE

(ALLOW 4-6 WEEKS FOR DELIVERY)

___________ EACHVIDEOPROGRAM ___________CONSISTSOF ________

@1@ii@UNLESSOThERW@ENOTED______Full set ofvideos, $386

0 CAN-405V (2cassettes,$78.00)PlenarySession:BiOlOgicalandClinicalRolesofGeneticMarkers

0 CAN-41IV@ G.H.A.OowesMemo@lAwai,@dLecture:GeneticAnalysisofllumanBreastCaneer,Mary-ClaireKing

0 CAN-422VPresidentialAddress:1WRadiationandImmunology:SomethingNewundertheSun,MargaretL.Kiipke;PresentationOftheSecOIIdGertnideElba CancerResearchAward

0 CAN-423V (2cassettes,$7&fX3)MinoñtyIssuesCommltteeSymposium:SurvivalandSuccessinCancerResearch:TowardtheYear2000

0 CAN-438VThirdAmericanCancerSocietyAwardLectureonCancerEpidemiologyandPtevention:ThePreventlonofHormone-inducedCancers,BrianE.Henderson

0 CAN-463V EighteenthRichardandHindsRosenthalFonndationAwardLecture:Angiogenesisasa TargetforCancerTherapy, Marc E. Lippman

0 CAN-464VPublicEducationSession:TheFundingCrisisinCancerResearch:WhatCanWeDo?

0 CAN-474VThirteenthCorneliusP.RhoadsMemorialAwardLecture:GeneticSuppressorElements:NewToolsforMolecularOncology,IgorB.Roninson

0 CAN-486V ThirteenthBruceF.CainMemorialAwardLecture:CamptothecinandTaxol: From Discovery to Clnlcal Usage, MansukhC. Waniand MonroeE.Wall

VIDEO ORDERS(Pleasecheckone)0 VHS0 PAL($15conversion surcharge)

0 CHECKENCLOSEDPAYABLETOTEACH‘EM0 VISA $25MINIMUMONCREDITCARDORDERS0 i@ic CARD#_____________________0 1w@x EXPIRATIONDATE______________TOTAL(INU.S.FUNDS)S__________

PLEASE NOTE: Any defective tapes will be replaced. but tapes are nonrefundable.

The genetic basis of cell signaling, apoptosis/programmedcell death,anddrug resistancedrive the design of several catting edge therapiessuch asclinical studies with vitamin analogues or drugs that interfere with the resistanceof braintumorcells to conventionalchemotherapeuticagents.PCIinvestigators are pursuing the development and utility of gene vectors, such asretroviruses, adenoviruses, and liposomes, optimizing gene delivery to suchtarget cells as immune cells, fibroblasts, and tumor cells.

Researchon cancergrowthandmetastasesis promotinggreaterunderstanding of their biological mechanisms. Current investigations cover enzymesinvolved in metastasesand the propertiesof tumorendothelia,therebycontributing to clinical assays that predict an individual tumor's invasiveness.Genetherapy,thefirstat theUniversityof PittsburghMedicalCenter,initiatedfor patientswith advancedcancer,involved injectingpatientswith fibroblaststransfectedwiththegene forinterleukin4. Also thisyear,PCIresearchersusedanothernovel syntheticpeptidevaccine to treatadvancedcancer,basedon analtered form of mucin, which appears exclusively on cancer cells of the breast,colon, and pancreas.

On the basis of extremely promising preliminaryresearch,PCI is nowleadingan EasternCooperativeOncology GroupTrialcombiningchemotherapy and radiation for malignant gliomas. This year, a PCI-led multi-institutionalstudy showed thata specific combinationof chemotherapyandautologous bone marrow transplantation significantly improves survival of patientswith acute myelogenousleukemia.

PCIalso has been involved in the NCI-fundedProstateCancerPreventionTrial and the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trials.TheUniversityof Pittsburghis one of only 16 vanguardcentersofthe WomensHealthInitiative,which involves prospectivestudies of interventionsto preventbreastandcolorectalcancers.PCIhascreatedanenterprising,enormouslyproductive environment for cancer prevention, detection, diagnosis, and treatment,sustainedby the interplayof manydifferentresearchdisciplinesfocusedon translatingbasic findings to clinical initiatives.

Dr. Herberman,the first Directorof the PittsburghCancerInstitute,andrecentlyappointedthe firstHiIlmanProfessorof Oncology, is an internationally recognizedtumorimmunologistwhose majordiscoveries have fosterednovel approachesto cancer therapy.NK cell-mediatedcytotoxicity againsttumorswas firstdiscoveredin Dr. Herberman'slaboratoryin the early 1970s.His investigations into NK cells have demonstrated that stimulation of NKactivity by various immunomodulators leads to inhibition of metastases.

Dr. Herberman has also played a leading role in several other importantaspects of tumor immunology. During his 19 years at the Nd, these included:evidence for specific antitumor immunity to human tumors and their prognostic value; the organization of a national program of immunodiagnostic researchanda criticalapproachto the evaluationof tumormarkers;a majorrole in thedevelopmentof the Biological ResponseModifiersProgramof the NC!; andthe adoptionof a systematic,rationalapproachto the clinical investigationofbiological response modifiers. Much of his currentresearchfocuses on thesystematic evaluation of interleukin 2-stimulated NK cells for their therapeuticefficacy and prolongationof survival,especially in the treatmentof minimalresidualdiseasefollowing conventionaltreatmentby surgeryor chemotherapyor both.

Dr. Herberman'sachievementshavebeen recognizedby numerousawards,includingthe Governorof Pennsylvania'sAward for Excellence in Scienceand Medicine, a Lifetime Science Award from the Institutefor AdvancedStudies in Immunology and Aging, and the Solomon A. Berson MedicalAlumni AchievementAward in Clinical Science from his alma mater,NewYork University. Dr. Herbermanwas one of the 100 most-cited researchauthors for the period 1981—1990.He has been an active member of theAmerican Association for Cancer Research since 1969, residing on the Boardof Directorsfrom 1987—1990and currentlyserving on the Public EducationCommittee.

We areindebtedto Dr. Herbermanfor the informationandphotographsforthis cover feature.

Sidney Weinhouse

COVER LEGEND.

Cancer Research

While the University of Pittsburgh has a long tradition of excellence incancer research, the Pittsburgh Cancer Institute (PCI), created in 1984, galvanized the University'sefforts in clinical oncology and basic cancerresearch.Established by a consortium of medical and academic institutions including theUniversity of Pittsburgh Medical Center and Carnegie Mellon University, PCIhas rapidlybecome an internationalforce in cancer research.Within threeyears of its creation, PCI became a National Cancer Institute (NCI)-designated

Clinical Cancer Research Center, and it won an NC! designation as a Cornprehensive Cancer Center just two years later.

PCIis recognizedinternationallyfor researchin the immunologyof cancerand biological responsemodifiers,a fact thatcan be attributedlargely to theDirector, Ronald B. Herberman (cover), and to the talented group of scientistsandclinicianshe hasrecruited.WithDr.Herberman'sleadershipandextensivemultidisciplinary interactions among investigators, PCI has rapidly translatedmany basic research findings into clinical applications.

The Institute'sbasic researchprogramsinclude characteristicsof tumormicrovasculature, mechanism(s) of tumor angiogenesis, tumor invasion andcancer metastasis, and many aspects of cancer immunology, including cellular,molecular,and psychoneuralcomponents;and the molecularprocesses andgenetic events required for the initiation and progression of cancer. TwoNCI-funded grants that highlight effective basic and clinical collaboration arespecialized programs of research excellence (SPORE) awards in lung and ingastrointestinal cancer. Both the lung and gastrointestinal programs work withthe PCI's tissue/serum bank, a resource for multidisciplinary investigations ofearly detection biomarkers and genetic markers.

PCI ranks high among cancer centers in investigationsof biological response modifiers (BRMs). The Biological Therapeutics Program conductsnumerousbasic andclinical researchstudieson such BRMsas interferonsandinterleukins 2, 4, 7, 10, and 12. The Immunologic Monitoring and DiagnosticsLaboratory is unique among cancer centers for its monitoring of the effects ofBRMs. It monitors the immunological parametersof each cancer patientenrolled in a PCI clinical trial using BRMs and preparescells and othermaterials for administration to patients on vaccine or adaptive cellular therapytrials.

The clinical rangeof BRM use is broad.Granulocyte-macrophagecolonystimulating factor and interleukin 2 are being used for hematological cancerpatients undergoing bone marrow transplantation and/or peripheral blood stemcell transplantation. Interferons are being used experimentally to treat patientswith melanoma, colon cancer, or thyroid cancer. Natural killer (NK) cells,tumor-infiltrating lymphocytes, and various interleukins are being used to treata variety of solid tumors.